EGCG for RTD Beverages: Solubility & Stability Guide
The physical chemistry guide for formulators sourcing EGCG for clear, stable, low-sediment
A functional beverage brand launches an RTD green tea supplement containing 200 mg EGCG 98% per 330 mL bottle at pH 3.5. Within three weeks of production, field returns begin — visible white crystalline sediment at the bottle base. QC testing confirms the EGCG has partially recrystallized out of solution. The EGCG powder used was a standard crystalline grade with D90 particle size of 180 µm and no dispersibility optimization for liquid matrices.
This is the most common and most avoidable EGCG formulation failure in RTD beverage development — and it originates entirely at the ingredient sourcing stage. The choice between crystalline, micronized, or amorphous EGCG powder determines not only whether the ingredient goes into clean suspension, but also whether the finished product generates consumer-perceptible astringency and whether the EGCG degrades faster than shelf-life modeling predicts.
For clear RTD functional beverages, amorphous or micronized EGCG with D90 ≤50 µm or D50 ≤10 µm is strongly preferred over standard crystalline EGCG (D90 >100–200 µm). Crystalline EGCG monohydrate has a tightly ordered lattice requiring significant energy to dissolve at RTD processing temperatures (20–25°C cold fill). Amorphous EGCG has a disordered molecular arrangement with higher free energy and higher apparent aqueous solubility — enabling faster, more complete dissolution. Solubility of pure crystalline EGCG 98% in water: approximately 4.6 mg/mL (4.6 g/L) at 25°C. With sucrose as hydrotropic agent: approximately 26.7 mg/mL — a 5.8× improvement. Astringency threshold for EGCG in solution: approximately 60–90 mg/L (0.06–0.09 mg/mL). EGCG is maximally stable at pH 3–4.5 (rate constant at pH 3 / 25°C: k = 1.06 × 10⁻⁷ s⁻¹). Above pH 5, degradation accelerates significantly. Suppliers should be audited for powder particle morphology by SEM and dissolution kinetics by DLS — not just HPLC purity.
- Introduction: Physical Chemistry of EGCG in Liquid Matrices
- Crystalline vs. Amorphous EGCG: Structural Differences and Solubility
- Technical Parameter Table: Free Crystalline vs. Amorphous EGCG
- Astringency and Bitterness: Thresholds, Catechin Ranking, and Mitigation
- pH-Dependent Degradation Kinetics: Rate Constants and Stability Zones
- Supplier Audit: SEM Morphology, DLS Particle Sizing, and Dispersibility
- RTD Formulation Stack: Stabilizers, pH Targets, and Dissolution Aids
- Blue Eyes Biotech Solution: Custom-Milled High-Dispersibility EGCG 98%
- FAQ
1. Introduction: Physical Chemistry of EGCG in Liquid Matrices
EGCG (epigallocatechin-3-gallate; MW 458.4 g/mol; CAS 989-51-5) is a galloylated catechin with a flavan-3-ol core with a trihydroxylated B-ring (the pyrogallol moiety) and a galloyl ester at the 3-OH position. This molecular architecture drives three formulation-critical physical behaviors simultaneously:
- Self-association and crystallization — EGCG molecules form extensive intermolecular hydrogen bond networks through multiple adjacent hydroxyl groups. In acidic aqueous solution, these drive concentration-dependent self-aggregation and eventual crystal nucleation and growth, producing the visible sedimentation seen in poorly formulated RTD products.
- Salivary protein binding (astringency) — The same hydroxyl groups bind avidly to proline-rich salivary proteins (PRPs) and mucins, cross-linking and precipitating them. This protein-polyphenol complex formation at the oral mucosal surface is the mechanistic basis of astringency.
- Oxidative and alkaline degradation — The B-ring pyrogallol moiety and galloyl ester bond are susceptible to pH-dependent hydrolysis and oxidation. EGCG is the most degradation-susceptible catechin, with first-order degradation kinetics strongly accelerated by increasing pH and temperature.
Standard crystalline EGCG 98% exists predominantly as a monohydrate crystal form stabilized by an extensive 3D hydrogen bond network between adjacent EGCG molecules and water of crystallization. Breaking this lattice requires sufficient thermodynamic driving force — which at cold-fill RTD conditions (20°C, pH 3.5) may not exist above approximately 4–5 mg/mL EGCG. Cold storage at 4°C, reduced co-solute concentration, and variable water activity during shelf life can push the system into a supersaturated, nucleation-prone state. Once crystal nuclei form, recrystallization proceeds rapidly. Micronized or amorphous EGCG dissolves faster and maintains thermodynamic solution stability longer under these conditions.
2. Crystalline vs. Amorphous EGCG: Structural Differences and Solubility
Crystalline EGCG (standard grade): long-range ordered monohydrate crystal lattice; seven distinct crystalline forms characterized via crystal engineering screening (ACS Mol. Pharmaceutics, 2013); thermodynamically stable ground state; sharp XRPD diffraction peaks; relatively low free energy; requires significant lattice energy to dissolve. Solubility in purified water (pure EGCG 98%): approximately 4.6 mg/mL at 25°C. In PBS pH 7.2: approximately 25 mg/mL (partial ionization of phenolic OH above pKa).
Amorphous EGCG: disordered molecular arrangement; no long-range crystal lattice; higher free energy (thermodynamic instability → higher apparent solubility); broader XRPD halo pattern; higher hygroscopicity than crystalline form (moisture absorption accelerates recrystallization); significantly faster dissolution. Produced by spray-drying from solution, freeze-drying, or rapid precipitation with inhibitory polymers. The higher apparent solubility is the thermodynamic driving force exploited for clear beverage formulation — but requires humidity-controlled packaging to prevent recrystallization during storage.
Micronized crystalline EGCG: jet-milled or impact-milled to D50 ≤5–10 µm while retaining crystallinity. Smaller particle size dramatically increases surface area (∝ 1/d), accelerating dissolution kinetics without the thermodynamic instability of fully amorphous form. Crystal engineering screening of EGCG found cocrystals with GRAS co-formers showing modified aqueous solubility. Sucrose forms H-bond complexes with EGCG's hydroxyl groups — demonstrated at 26.7 mg/mL at 25°C (Secretan et al., Pharmaceuticals, 2021), a 5.8-fold improvement, with interaction energies >130 kJ/mol confirmed by DFT modelling.
3. Technical Parameter Table: Free Crystalline vs. Amorphous EGCG for RTD
| Parameter | Free Crystalline EGCG 98% (Standard) | Micronized Crystalline EGCG (D50 ≤10 µm) | Amorphous / Spray-Dried EGCG | EGCG–Sucrose Complex (Solution) |
|---|---|---|---|---|
| Solid-State Structure | Long-range ordered monohydrate crystal; sharp XRPD peaks; low free energy thermodynamic ground state | Crystalline lattice retained; particle size mechanically reduced; possible surface amorphization at extreme milling energies | No long-range order; broad XRPD halo; high free energy metastable state; DSC shows Tg (glass transition) | EGCG in solution complexed with sucrose via H-bonding; no distinct solid-state form |
| Aqueous Solubility at 25°C | ~4.6 mg/mL in purified water, pure EGCG 98% | Apparent solubility same as crystalline; dissolution rate significantly faster due to increased surface area | Higher apparent solubility than crystalline (elevated free energy thermodynamic driving force) | ~26.7 mg/mL at 25°C in sucrose formulation (~5.8× improvement) |
| Dissolution Rate | Slow — D90 typically 100–200 µm; low surface area; incomplete dissolution at RTD processing temperatures | Fast — surface area ∝ 1/diameter; D50 ≤10 µm; dissolution in seconds to minutes vs. hours | Fastest — higher surface area AND higher thermodynamic driving force; near-complete within minutes at room temperature | Instantaneous at preparation stage; solution stability is the formulation challenge |
| Sedimentation Risk in RTD (pH 3–4) | High — undissolved crystals settle within days to weeks; risk increases at cold storage and low co-solute concentration | Low to moderate — smaller particles remain suspended longer; risk of recrystallization still exists at supersaturation | Low — faster complete dissolution; risk shifts to recrystallization from solution if amorphous partially reverts during storage | Lowest — in-solution complexation; sedimentation minimal if pH and sucrose maintained |
| Astringency at 200 mg / 330 mL (≈0.61 mg/mL) | At 610 µg/mL: above published astringency threshold (60–90 mg/L); perceivable at moderate intensity — depends on matrix | Same EGCG concentration in solution → same astringency at equivalent dissolved concentration | Same astringency at equivalent dissolved EGCG; faster dissolution may increase early perception | Sucrose co-complexation may modestly mask astringency; acidic pH reduces salivary protein precipitation speed |
| pH Stability Optimum | pH 3.0–4.5; k = 1.06 × 10⁻⁷ s⁻¹ at pH 3 / 25°C (lowest degradation); unstable above pH 5 | Same as crystalline once dissolved — pH behavior is a solution-phase phenomenon | Same as crystalline once dissolved; amorphous powder may show marginally faster solid-state oxidation if poorly packaged | Optimal pH 3.5–4.5; sucrose reduces metal ion-catalyzed oxidation; glucose acts as radical scavenger |
| Packaging / Storage | Moderate — sealed packaging with desiccant; light protection; avoid humidity >60% RH | Moderate-high — larger surface area increases hygroscopicity; nitrogen purge recommended | High — significantly more hygroscopic; sealed moisture-barrier packaging, nitrogen inert atmosphere, silica gel, 2–8°C for long-term storage | High — liquid formulation; amber glass or opaque PET; nitrogen headspace; 2–8°C |
| Relative Cost | Baseline — standard commercial grade | 10–25% premium — milling and characterization add cost | 20–40% premium — spray-drying, stabilizer formulation, enhanced packaging | Custom formulation pricing |
Table 1 — EGCG Physical Forms: Full Technical Comparison for RTD Beverage Formulation
4. Astringency and Bitterness: Thresholds, Catechin Ranking, and Mitigation
EGCG-induced astringency is a tactile chemesthetic sensation arising from cross-linking precipitation of proline-rich proteins (PRPs) and mucins in the oral mucosal pellicle. EGCG's eight total phenolic OH groups form multidentate hydrogen bonds with proline carbonyl groups and hydrophobic regions of salivary PRPs. Above the critical threshold, these interactions form insoluble EGCG–protein aggregates that reduce oral lubrication — perceived as "drying," "puckering," or "roughening." Galloylation is a key structural determinant: galloylated catechins (EGCG, ECG) exhibit higher astringency than non-galloylated (EGC, EC) due to the additional galloyl group's contribution to protein binding affinity.
Published thresholds (human sensory panel, triangle test methodology): Astringency threshold: 60–90 mg/L (0.06–0.09 mg/mL); Bitterness threshold: 40–150 mg/L (0.04–0.15 mg/mL). Catechin astringency ranking (at equal concentration): ECG > GCG > EGCG > EGC > EC. At 200 mg EGCG in 330 mL (0.61 mg/mL = 610 mg/L): approximately 7–10× above the astringency threshold — significant sensory management required.
| Catechin | Astringency Threshold (mg/L) | Bitterness Threshold (mg/L) | Relative Astringency vs. EGCG | Galloylated? | Dominant in EGCG 98%? |
|---|---|---|---|---|---|
| ECG | ~60 mg/L (strongest) | ~40 mg/L | Highest | Yes | Minor (<2%) |
| GCG | ~85 mg/L | ~60 mg/L | High | Yes | Trace |
| EGCG | ~60–90 mg/L | ~40–150 mg/L | High | Yes | Dominant (≥98%) |
| EGC | ~80–90 mg/L | ~150 mg/L | Moderate | No | Trace |
| EC | ~60 mg/L (lowest astringency) | ~60–100 mg/L | Low | No | Trace |
Table 2 — Catechin Astringency and Bitterness Thresholds (Human Sensory Panel Data)
1. Acidic pH (3.0–4.5): At pH below 4, EGCG phenolic OH groups are predominantly protonated, reducing hydrogen-bonding affinity for salivary proteins. Primary astringency suppressor — also stabilizes EGCG.
2. Sucrose co-formulation (6–12% w/v): Competitive complexation reduces available EGCG binding sites for salivary proteins; simultaneously improves solubility ~5.8×.
3. Ascorbic acid (0.05–0.2% w/v): Scavenges oxidizing species; regenerates EGCG from early oxidation intermediates; chelates trace metal ions that catalyze EGCG degradation.
4. Limit EGCG to ≤100 mg/330 mL for mainstream consumer acceptance in a well-formulated matrix without masking agents.
5. Encapsulation (for high-dose applications): Casein micelle or chitosan-TPP nanoparticles; EE >80%; protects sensory receptor from free EGCG contact; adds cost and complexity.
5. pH-Dependent Degradation Kinetics: Rate Constants and Stability Zones
EGCG degradation follows pseudo-first-order kinetics across pH 2.2–8.0 with rate constants strongly pH- and temperature-dependent following the Arrhenius equation. Published data (Wang et al., 2006, 2008; Food and Bioprocess Technology, 2019): k at pH 3 / 25°C = 1.06 × 10⁻⁷ s⁻¹ (lowest, most stable); k at pH 8 / 135°C = 8.83 × 10⁻² s⁻¹ (highest tested, 83,000× faster). Epimerization of EGCG to GCG increases with both temperature and pH. Stability by pH zone at ~25°C: pH 1.6 → stable up to 96 h; pH 5 → ~48 h; pH 7 → ~24 h; pH 9 → ~4 h. Clinical oral formulation (Secretan et al., 2021) with pH 3.5 + sucrose + ascorbic acid + glucose: 12–24+ months stability demonstrated.
| pH Zone | Temperature | Approximate Stability | Primary Degradation Mode | RTD Application |
|---|---|---|---|---|
| pH 1.6–3.0 | 25°C | >96 h (>4 days) | Minimal; protonated state limits oxidation | Optimal — very acidic beverages (energy drinks pH 2.8–3.2) |
| pH 3.0–4.5 | 4–25°C | Weeks to months at cold storage with antioxidants | Slow epimerization; minimal oxidation at low temperature | Target zone — most commercial RTD tea beverages |
| pH 4.5–5.5 | 25°C | <48 h at room temperature | Epimerization dominant; oxidative degradation begins; yellowing | Caution — requires antioxidant protection and N₂ headspace |
| pH 5.5–7.0 | 25°C | <24 h | Rapid oxidative degradation; galloyl ester hydrolysis; browning | Avoid — incompatible with EGCG stability for RTD |
| pH >7.0 (alkaline) | Any | Minutes to hours | Near-instantaneous oxidation; EGCG auto-oxidation and dimerization | Incompatible — EGCG cannot be formulated in alkaline matrices |
| pH 3.5–4.0 + sucrose + ascorbic acid | 4°C storage | 12–24+ months (validated clinical data) | Epimerization minimal; oxidation suppressed | Gold standard — optimized RTD shelf-life formulation stack |
Table 3 — EGCG pH Stability Zones: Degradation Rate Summary and RTD Application Guidance
Hot-fill RTD processing (typically 85–93°C fill temperature) dramatically accelerates EGCG degradation even at acidic pH. At 80°C / pH 5: t₉₀ ≈ 544 min (~9 hours). At 120°C / pH 7: 30% EGCG remaining after only 105 minutes. For hot-fill applications: (a) use cold-fill or flash-pasteurization (HTST: 72°C for 15 seconds); (b) maintain pH ≤3.8 throughout; (c) fill under nitrogen; (d) perform HPLC catechin profile at fill and at 1, 3, 6, 12 months. Do not extrapolate stability from ambient pH 3 data to hot-fill conditions without independent validation.
6. Supplier Audit: SEM Morphology, DLS Particle Sizing, and Dispersibility
Standard EGCG 98% suppliers characterize by HPLC purity, heavy metals, moisture, and residual solvents. Fewer than 20% of commercial EGCG suppliers maintain analytical capability to provide powder morphology by SEM, particle size by laser diffraction, dissolution kinetics profiles, or DLS on dispersed particle populations. This analytical gap is the primary reason formulators receive purity-compliant EGCG that fails in liquid application.
| SEM Observation | Interpretation for RTD Formulation | Action |
|---|---|---|
| Large prismatic crystals, D90 >100 µm | Standard crystalline grade; slow dissolution; high sedimentation risk | Reject for RTD without milling |
| Needle-like habit, high aspect ratio (>10:1) | Needles settle rapidly; mechanically weak; irregular PSD | Conditional — micronize before beverage use |
| Irregular angular particles, smooth surfaces, D50 ≤10 µm | Jet-milled crystalline EGCG; good dissolution kinetics; confirm crystallinity by DSC | Accept with dissolution profile verification |
| Spherical particles, smooth surfaces (spray-dried morphology) | Spray-dried amorphous EGCG; fastest dissolution; confirm amorphicity by XRPD (broad halo) and DSC (Tg) | Accept with amorphicity and dissolution confirmation |
| Highly aggregated clusters, surface fusion visible | Moisture-induced aggregation; inadequate packaging; dissolution unpredictable | Reject batch — storage non-compliance |
Table 4 — SEM Morphology Interpretation for EGCG Powder Qualification in RTD Sourcing
Test matrix: Disperse EGCG at 2 mg/mL in simulated RTD matrix (pH 3.5 citric acid/sodium citrate buffer, 8% sucrose w/v, 25°C); mix by inversion 10×; equilibrate 5 min; inject into DLS cuvette without filtration.
DLS parameters: ISO 13321 / ISO 22412; measurement temperature 25°C; equilibration 120 s; 3 × 10 runs; backscatter geometry (173°); z-average hydrodynamic diameter (Dh) and PDI reported.
Acceptance criteria for RTD-compatible EGCG:
Z-average Dh ≤500 nm → Accept — nanoscale; Brownian motion exceeds gravitational settling; beverage will remain visually clear.
Z-average Dh 500 nm–5 µm → Conditional — visible turbidity likely; sedimentation possible; may be acceptable in opaque formats.
Z-average Dh >5 µm → Reject for clear RTD — rapid sedimentation (hours to days).
Stokes settling reference: At r = 100 µm (standard crystalline D = 200 µm): settling velocity ≈ 6 mm/h — visible sedimentation within hours. At r = 5 µm (D = 10 µm, micronized): v ≈ 0.015 mm/h — negligible over shelf life.
Supplier COA Audit Checklist for EGCG in RTD Applications
- HPLC purity (mandatory baseline): EGCG ≥98%; full individual catechin profile; caffeine ≤0.1% if decaffeinated; USP <621>; Rs between EGCG and GCG peaks ≥2.0.
- Particle size by laser diffraction (ISO 13320): D10, D50, D90 reported; for RTD: D50 ≤10 µm (micronized) or D90 ≤50 µm minimum; batch-specific data.
- SEM images (first qualification batch): Two magnification levels (500× and 2,000×); scale bar annotated; crystal habit and aggregation state described.
- Solid-state characterization (amorphous grades): XRPD pattern showing amorphous halo; DSC thermogram confirming Tg and absence of crystalline melt endotherm; crystallinity index ≥90% amorphous for spray-dried EGCG.
- Dissolution profile in simulated RTD matrix: % EGCG dissolved vs. time in pH 3.5 citrate buffer, 25°C, at specified concentration; ≥95% dissolved within 30 min for micronized/amorphous grades.
- DLS dispersibility in simulated beverage matrix: Z-average Dh and PDI at 2 mg/mL in pH 3.5 buffer/sucrose; z-average Dh ≤500 nm for clear beverage claims.
- Moisture and hygroscopicity: LOD by Karl Fischer; moisture sorption isotherm at 40°C/75% RH to assess recrystallization risk during storage and tropical climate shipping.
Disqualification Triggers for RTD EGCG Sourcing
- No particle size distribution data — supplier cannot characterize powder beyond HPLC purity
- D90 >150 µm with no micronization option
- No SEM morphology data for first qualification batch
- No dissolution profile — "dissolves well in warm water" without time/concentration/temperature data
- No DSC or XRPD for claimed amorphous/spray-dried EGCG
- No moisture sorption data for amorphous EGCG — unknown recrystallization risk in supply chain
7. RTD Beverage Formulation Stack
| Component | Function | Recommended Level | Mechanism | Regulatory Status |
|---|---|---|---|---|
| pH 3.5–4.0 (citric acid + sodium citrate) | Primary stability control; astringency suppression | pH 3.5 ± 0.2 (batch-specific measurement) | Protonation of EGCG OH reduces protein-binding affinity and oxidation; citric acid chelates trace metal ions | GRAS; food-grade |
| Sucrose (or sucrose + erythritol) | Hydrotropic solubilizer; astringency masking; EGCG stability enhancer | 6–12% w/v; ≥6% for meaningful solubility enhancement | H-bond complexation between EGCG and sucrose OH groups increases apparent solubility ~5.8× and competes with salivary protein binding | GRAS; ubiquitous |
| Ascorbic acid (Vitamin C) | Antioxidant; radical scavenger; metal chelation co-factor | 0.05–0.2% w/v | Preferentially scavenges dissolved O₂ and ROS before they oxidize EGCG; regenerates EGCG from early oxidation intermediates | GRAS; nutrient in many jurisdictions |
| Nitrogen headspace | Dissolved oxygen removal; aerobic degradation prevention | Headspace O₂ ≤0.5%; DO in product ≤0.5 mg/L | EGCG oxidation is O₂-dependent; removing dissolved O₂ is the single most impactful process intervention | N₂ GRAS; process gas |
| Xanthan gum or gellan gum (low level) | Rheology modifier; sedimentation prevention for micronized grades | 0.01–0.05% w/v | Even trace hydrocolloid dramatically increases low-shear viscosity, slowing Stokes settling without affecting mouthfeel | GRAS; E415, E418 |
| Amorphous EGCG (D50 ≤5 µm or spray-dried) | Primary solubility engineering — ingredient selection | Specified grade replacing standard crystalline | Eliminates undissolved particle fraction by maximizing dissolution kinetics at ambient temperature | Same GRAS/food regulatory status as crystalline EGCG |
Table 5 — RTD Beverage Formulation Stack for EGCG Stability, Clarity, and Astringency Management
8. Blue Eyes Biotech Solution: Custom-Milled High-Dispersibility EGCG 98%
Custom-Milled EGCG 98% — Engineered for Clear Liquid Applications
Blue Eyes Biotech's high-dispersibility EGCG 98% is produced from the same water-crystallized EGCG 98% base material used for our standard capsule-grade, then subjected to controlled jet-milling and surface-treatment to achieve particle morphology specifications optimized for RTD beverage application. Same chemically pure EGCG molecule — controlled physical form addressing sedimentation, dissolution kinetics, and astringency management.
Why most suppliers cannot offer this: Producing pharmaceutical-grade micronized EGCG requires: (a) starting material of documented crystallinity (XRPD confirmed) for predictable milling behavior; (b) controlled-energy jet milling with inline particle size feedback — excessive milling induces partial surface amorphization; (c) inert atmosphere milling to prevent oxidative degradation; (d) post-milling particle size confirmation by laser diffraction on every production batch; (e) DLS dispersibility testing in simulated beverage matrix as a release criterion. Commodity EGCG suppliers with no particle engineering capability cannot reliably supply this specification.
High-Dispersibility EGCG 98% — Specification:
- EGCG assay: ≥98% (HPLC; USP <621>; Rs EGCG/GCG peaks ≥2.0)
- Particle size: D50 ≤5 µm; D90 ≤20 µm (laser diffraction ISO 13320, dry dispersion)
- SEM morphology: Batch SEM images provided; irregular angular habit; no crystal aggregation at 2,000×
- DLS dispersibility: Z-average Dh ≤300 nm at 2 mg/mL in pH 3.5 citrate/sucrose matrix at 25°C
- Dissolution profile: ≥95% dissolved within 15 min in pH 3.5 / 25°C simulated RTD matrix at 1 mg/mL
- Caffeine: <0.1% (decaffeinated grade for clean-label beverage positioning)
- Heavy metals (ICP-MS): Pb ≤0.5 ppm; Cd ≤0.1 ppm; As ≤0.2 ppm; Hg ≤0.1 ppm
- Moisture (KF): ≤5.0%; moisture sorption data at 25°C/60% RH and 40°C/75% RH available
- Packaging: Triple-ply aluminum foil laminate; nitrogen flush; silica gel; 2–8°C recommended for amorphous grades
Formulation support available: pH stability modeling for your specific beverage matrix; astringency assessment at your target EGCG concentration; compatibility screening with common beverage excipients; accelerated stability protocol design (40°C/75% RH HPLC monitoring schedule).
Specify standard crystalline EGCG 98% when: solid dosage form (capsule, tablet, sachet, powder blend); dissolution kinetics in beverage not relevant; cost minimization is primary criterion.
Specify micronized EGCG 98% (D50 ≤10 µm) when: RTD beverage with moderate EGCG (≤100 mg/330 mL); sucrose >6% and pH 3.0–4.0; clear appearance required but not water-clear; cost sensitivity moderate.
Specify high-dispersibility amorphous EGCG 98% when: water-clear or lightly colored RTD; EGCG ≥150 mg/330 mL; cold-fill at 20–25°C; clean-label prohibits rheology modifiers; shelf life ≥12 months required; DLS Dh ≤300 nm required by formulation specification.
Request a Free 20g Sample — High-Dispersibility EGCG 98%
Evaluate in your own RTD matrix. Batch-specific COA with particle size (D50/D90), SEM images, DLS dispersibility data, and full HPLC catechin profile available upon request.
For Direct Inquiries & Formulation Technical Support
Our team is available for beverage matrix compatibility screening, dissolution profile evaluation, and custom EGCG grade specification support.
Email: [email protected]
9. FAQ
At 0.61 mg/mL EGCG total, you are below the aqueous solubility limit (~4.6 mg/mL) and well below solubility in a sucrose matrix (~26.7 mg/mL). The risk is not solubility-limited sedimentation — it is kinetic recrystallization from supersaturated zones during cold storage if the EGCG powder was not fully dissolved during processing. Mitigation: (a) use micronized EGCG with D50 ≤5 µm to ensure complete dissolution during cold-fill; (b) verify by DLS in your specific matrix — not just pure water — that no particles above 500 nm remain post-formulation; (c) add 0.02–0.03% xanthan gum as anti-settling insurance; (d) maintain pH ≤4.0 throughout shelf life. These four steps eliminate RTD sedimentation in the vast majority of EGCG beverage formulations at this concentration.
Yes — amorphous and crystalline EGCG are the same molecule: (−)-epigallocatechin-3-gallate, CAS 989-51-5, MW 458.4 g/mol. The amorphous vs. crystalline distinction is a solid-state physical property, not a chemical distinction. Once dissolved in HPLC mobile phase (50% methanol/water, acidified), both forms produce identical chromatographic profiles — same retention time, same UV spectrum, same peak area per unit mass. HPLC cannot distinguish crystalline from amorphous EGCG. Solid-state differentiation requires XRPD (broad halo = amorphous; sharp peaks = crystalline) and DSC (Tg = amorphous; sharp endotherm = crystalline). Amorphous EGCG is not a "novel ingredient" — same dietary ingredient in a different physical form, no new regulatory pathway required.
At 610 mg/L, you are ~7–10× above the astringency threshold. Options in priority order: (1) Reduce pH to ≤3.5 — the single most cost-effective suppressor; protonation reduces protein-binding affinity; (2) Increase sucrose to ≥10% w/v — competitive complexation; (3) Add citric acid to 0.3–0.5% — chelates trace metals, mildly suppresses EGCG-protein aggregation; (4) Reduce EGCG to 100 mg/330 mL — if label claim allows; (5) Switch to GTE 50% polyphenols at equivalent polyphenol dose — diluted catechin profile with lower EGCG/volume; (6) Encapsulation — casein micelle or cyclodextrin inclusion complex. Do not switch to ECG to reduce astringency — ECG is actually more astringent than EGCG at equal concentration.
Realistic EGCG retention benchmarks: (a) pH 3.5 / 4°C / N₂ headspace: ≥85% EGCG retained at 12 months; (b) pH 3.5 / ambient 25°C / N₂ headspace: 60–75% at 12 months; (c) pH 3.5 / ambient / air headspace: <50% at 12 months. Verification protocol: HPLC catechin profile (all 7 catechins individually quantified) at T=0, 1, 3, 6, 9, 12 months; monitor for GCG increase (epimerization indicator), total catechin decline (degradation), and appearance (yellowing = oxidative browning). Label claim must reflect end-of-shelf-life EGCG content — design with 15–20% overfill at T=0 to support label claim throughout shelf life.
EU Regulation 2022/2340 applies specifically to food supplements. A 200 mg EGCG RTD beverage positioned as a functional beverage rather than a food supplement may not fall under the food supplement definition — classification depends on the product's presentation, marketing, and the EU member state's regulatory interpretation. If classified as a food supplement, the 800 mg/day EGCG cap and four mandatory warnings apply. If classified as a functional food or conventional food, standard food safety assessment applies. This classification decision should be made before EU market entry in consultation with EU regulatory affairs counsel, not at the formulation stage.
Related Blue Eyes Biotech Knowledge Center Articles
- Managing EGCG Epimerization in Liquid Formulations — Temperature, pH, and Stability Data
- EGCG 98% Technical Data Sheet — Full Specification, COA Parameters, and Test Methods
- HPLC vs. UV-Vis for EGCG: How False Purity Readings Are Generated and Detected
- Navigating EU Regulation 2022/2340: Green Tea Extract & EGCG Compliance Guide
- Sourcing Decaf Green Tea Extract Below 0.1% Caffeine
- EGCG Green Tea Extract: Complete B2B Sourcing and Buyer Guide
